Analysts Set Expectations for NTLA FY2027 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at Brookline Capital Markets reduced their FY2027 EPS estimates for Intellia Therapeutics in a research note issued to investors on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn $0.92 per share for the year, down from their previous estimate of $0.97. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.28) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics’ FY2028 earnings at $5.15 EPS.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). The firm had revenue of $7.16 million for the quarter, compared to analyst estimates of $9.74 million. Intellia Therapeutics had a negative net margin of 805.75% and a negative return on equity of 64.74%. Intellia Therapeutics’s revenue for the quarter was down 47.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.92) earnings per share.

Other equities analysts have also recently issued reports about the stock. Wedbush upped their price objective on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. Wall Street Zen cut Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Finally, Barclays began coverage on Intellia Therapeutics in a report on Tuesday, October 6th. They issued an “underweight” rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $21.44.

Intellia Therapeutics Stock Down 7.8%

Intellia Therapeutics stock opened at $11.17 on Monday. Intellia Therapeutics has a 12-month low of $7.95 and a 12-month high of $18.48. The firm’s fifty day moving average price is $12.05 and its 200 day moving average price is $13.02.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in shares of Intellia Therapeutics during the second quarter worth about $260,721,000. Sumitomo Mitsui Trust Group Inc. increased its holdings in Intellia Therapeutics by 24.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,605,623 shares of the company’s stock valued at $43,484,000 after buying an additional 708,094 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Intellia Therapeutics by 20.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,318,110 shares of the company’s stock valued at $29,709,000 after buying an additional 386,261 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Intellia Therapeutics during the first quarter valued at approximately $17,913,000. Finally, Bank of America Corp DE raised its stake in Intellia Therapeutics by 11.2% during the first quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock valued at $17,713,000 after buying an additional 139,325 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 9,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $11.99, for a total value of $107,910.00. Following the sale, the chief executive officer directly owned 1,138,064 shares of the company’s stock, valued at $13,645,387.36. This represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.50% of the stock is owned by corporate insiders.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $25 price target, offering a constructive counterpoint to the lower earnings forecasts. Analyst estimates
• Neutral Sentiment: Intellia plans to present at the Jefferies Global Healthcare Conference in London; the announcement did not include new clinical or financial information. Conference announcement
• Neutral Sentiment: A short-interest report claims a significant increase but lists short interest as zero shares, making the data internally inconsistent and difficult to interpret.
• Neutral Sentiment: The company reported inducement equity grants for new employees; the announcement provides no material business or clinical update. Inducement grants announcement
• Negative Sentiment: Analysts lowered projected earnings across multiple periods. The cuts reinforce concerns about Intellia’s expected losses and longer-term profitability, which may weigh on investor sentiment. Analyst estimates

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.